AIM

Business Context and Reporting Period

Company: Hemispherx BioPharma, Inc. (Note: Request metadata listed "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx BioPharma, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003
Business Overview: A biopharmaceutical company focused on developing nucleic acid-based therapeutics. Primary candidates include Ampligen(R) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and HIV. In March 2003, the company acquired assets related to Alferon N Injection(R) from Interferon Sciences, Inc. (ISI).

Key Financial Metrics

Liquidity: As of March 31, 2003, the company held approximately $3.4 million in cash and cash equivalents. Management anticipates needing approximately $5.4 million over the next 12 months to sustain operations.

Material Changes vs. Prior Period

• Revenue Decline: Revenues dropped from $613,000 in Q1 2002 to $66,000 in Q1 2003. The 2002 figure included a one-time $545,000 non-refundable license fee from a European distribution agreement. Q1 2003 revenue consisted of $47,000 from clinical treatment programs and $19,000 from initial sales of Alferon N.
• Expense Reduction: Total costs and expenses decreased by approximately $463,000 to $1.658 million. R&D expenses fell by $419,000 due to the completion of enrollment in the ME/CFS Phase III trial. G&A expenses decreased by $162,000, largely due to lower legal costs following the conclusion of the Asensio trial.
• Debt Issuance: In March 2003, the company issued $5.426 million in 6% Senior Convertible Debentures. Approximately $1.55 million of the proceeds were held back pending the acquisition of an ISI facility. This resulted in new long-term debt and current portion of long-term debt on the balance sheet.
• Asset Acquisition: The company acquired inventory and a limited license for Alferon N Injection, recording $1.829 million in inventory on the balance sheet.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Ampligen(R): The ME/CFS Phase III trial is fully enrolled (230 patients) with data analysis expected to begin in Q4 2003. An NDA filing with the FDA is targeted for Q2 2004. HIV Phase IIb trials are ongoing with 58 patients enrolled; completion costs are estimated between $3.0 and $4.0 million.
• Alferon N: The company expects to generate revenue from the sale of Alferon N, though commercial success depends on completing the second asset acquisition from ISI to secure the production facility.
• Capital Needs: Management believes current cash, anticipated debenture proceeds ($1.55 million), and Alferon N cash flows will fund operations for the next 12 months. However, additional financing may be required.

• ISI Acquisition Contingency: Failure to acquire the ISI facility within 90 days of the debenture issuance (by mid-June 2003) constitutes a technical default, potentially requiring the redemption of the debentures and severely impacting liquidity.
• Share Price Guarantee: The company guaranteed the value of approximately 1.43 million shares issued to ISI and its creditors at $1.59 per share. If the stock price is below this threshold on specific termination dates, the company must repurchase the shares, creating a potential liability of approximately $2.275 million.
• Regulatory Approval: Ampligen(R) remains investigational. There is no assurance of FDA approval for ME/CFS or HIV indications.
• Litigation: Pending appeals regarding the Asensio defamation case and product liability claims from clinical trial patients in the US and Belgium.

Investor Verification Checklist

• Debenture Default Risk: Verify the status of the second ISI asset acquisition (facility purchase) to ensure the $1.55 million held-back proceeds are released and the company avoids a debt default.
• Share Guarantee Liability: Monitor the company's stock price relative to the $1.59 guarantee price for the shares issued to ISI and creditors to assess potential future cash outflows for repurchases.
• Alferon N Commercialization: Confirm the timeline for ramping up production at the New Brunswick facility and the execution of marketing agreements to validate revenue projections.
• Cash Burn Rate: Review subsequent filings to ensure the company's cash position remains sufficient to fund the HIV clinical trials and ME/CFS data analysis without immediate dilutive equity raises.
• SEC Inquiry: Note the informal SEC inquiry regarding the valuation of the Alferon N inventory acquired from ISI and monitor for any restatements or regulatory actions.